107 related articles for article (PubMed ID: 7262915)
21. Detection of circulating immune complexes in human sera by simplified assays with polyethylene glycol.
Digeon M; Laver M; Riza J; Bach JF
J Immunol Methods; 1977; 16(2):165-83. PubMed ID: 881555
[TBL] [Abstract][Full Text] [Related]
22. C1q solid-phase enzymatic microassay for detection of circulating immune complexes: its application in human breast cancer.
Manzo C; Longo C; Bianchin A
Tumori; 1982 Feb; 68(1):47-52. PubMed ID: 7041380
[TBL] [Abstract][Full Text] [Related]
23. Circulating immune complexes in human acute leukaemia.
Balestrieri G; Tincani A; Cattaneo R; Rossi G; Verzura P; Marini G; Calculli G; Ferremi P; Marinone G
Br J Haematol; 1981 Oct; 49(2):269-74. PubMed ID: 6975116
[TBL] [Abstract][Full Text] [Related]
24. Detection of immune complex-like materials in cancer patients' sera: a comparative study of results obtained with the C1q deviation and C1q binding tests.
Rossen RD; Zubler RH; Day NK; Reisberg MA; Morgan AC; Gutterman JU; Hersh EM
J Lab Clin Med; 1978 Feb; 91(2):191-204. PubMed ID: 413872
[TBL] [Abstract][Full Text] [Related]
25. Circulating immune complexes and C1 activation in patients with rapidly progressive glomerulonephritis, before and after treatment with immunosuppression and plasma exchange.
Sjöholm AG; Brun C; Larsen S; Thysell H
Int Arch Allergy Appl Immunol; 1983; 72(1):9-15. PubMed ID: 6874103
[TBL] [Abstract][Full Text] [Related]
26. The IgG detected in the C1q solid-phase immune-complex assay is not always of immune-complex nature.
Hack CE; Belmer AJ
Clin Immunol Immunopathol; 1986 Jan; 38(1):120-8. PubMed ID: 3484437
[TBL] [Abstract][Full Text] [Related]
27. [Detection of circulating immune complexes by the C1q complement fraction deviation test. 1st application in the study of human glomerulopathies].
Sobel A; Gabay Y; Lagrue G
Nouv Presse Med; 1976 Jun; 5(23):1465-9. PubMed ID: 132639
[TBL] [Abstract][Full Text] [Related]
28. [Circulating immune complexes: optimization and characteristics of the C1q(I125) fixation test].
Caillot G; Lamelin JP; Hartmann DJ; Ville G
Pathol Biol (Paris); 1984 Nov; 32(9):931-7. PubMed ID: 6334270
[TBL] [Abstract][Full Text] [Related]
29. A solid-phase radioimmunoassay for C1q-binding immune complexes. I. Delta IgG as indicator molecule.
Svehag SE
Scand J Immunol; 1975; 4(7):687-97. PubMed ID: 1198070
[TBL] [Abstract][Full Text] [Related]
30. Lack of activation of C1, despite circulating immune complexes detected by two C1q methods, in patients with rheumatoid arthritis.
Hack CE; Eerenberg-Belmer AJ; Lim UG; Haverman J; Aalberse RC
Arthritis Rheum; 1984 Jan; 27(1):40-8. PubMed ID: 6318777
[TBL] [Abstract][Full Text] [Related]
31. [Circulating immune complexes, detection in human glomerulonephritis by the PEG-EDTA technique (author's transl)].
Laurent B; Gonthier R; Genin C; Toulon J; Laurent P; Sabatier JC; Berthoux FC
Pathol Biol (Paris); 1982 Mar; 30(3):141-6. PubMed ID: 6808442
[TBL] [Abstract][Full Text] [Related]
32. Significance of circulating immune complexes in pulmonary tuberculosis.
Samuel AM; Ashtekar MD; Ganatra RD
Clin Exp Immunol; 1984 Nov; 58(2):317-24. PubMed ID: 6437714
[TBL] [Abstract][Full Text] [Related]
33. Improved detection of immune complexes in human and mouse serum using a microassay adaptation of the C1Q binding test.
June CH; Contreras CE; Perrin LH; Lambert P
J Immunol Methods; 1979; 31(1-2):23-9. PubMed ID: 117056
[TBL] [Abstract][Full Text] [Related]
34. Comparison of three immunoassays for immune complexes in rheumatoid arthritis.
Gupta RC; McDuffie FC; Huston KA; Tappeiner G; Meurer M; Jordon RE; Luthra HS; Hunder GG; Ilstrup D
Arthritis Rheum; 1979 May; 22(5):433-9. PubMed ID: 87203
[TBL] [Abstract][Full Text] [Related]
35. Detection of IgA-class circulating immune complexes (CIC) in sera from patients with IgA nephropathy using a solid-phase anti-C3 Facb enzyme immunoassay (EIA).
Yagame M; Tomino Y; Miura M; Tanigaki T; Suga T; Nomoto Y; Sakai H
Clin Exp Immunol; 1987 Feb; 67(2):270-6. PubMed ID: 3301093
[TBL] [Abstract][Full Text] [Related]
36. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
Pearlstein E; Sorvillo J; Gigli I
J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
[TBL] [Abstract][Full Text] [Related]
37. Immunological aspects of Graves' disease patients in different clinical stages.
Gauna A; Segura G; Sartorio G; Soto R; Segal-Eiras A
J Endocrinol Invest; 1989 Nov; 12(10):671-7. PubMed ID: 2614006
[TBL] [Abstract][Full Text] [Related]
38. An analysis of the fluid phase C1q binding assay. The effect of endogenous C1q on the precipitation and detection of an immune complex model.
Jacobs RJ; Mocharla R
J Immunol Methods; 1988 May; 109(2):265-75. PubMed ID: 3258897
[TBL] [Abstract][Full Text] [Related]
39. The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer.
Rossen RD; Reisberg MA; Hersh EM; Gutterman JU
J Natl Cancer Inst; 1977 May; 58(5):1205-15. PubMed ID: 323505
[TBL] [Abstract][Full Text] [Related]
40. Clq binding activity in lupus erythematosus: correlation with the "lupus band test".
Tappeiner G; O'Loughlin S; Jordon RE
J Invest Dermatol; 1978 Apr; 70(4):187-90. PubMed ID: 305943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
